share_log

There's A Lot To Like About Shaanxi Panlong Pharmaceutical Group Limited By Share's (SZSE:002864) Upcoming CN¥0.22 Dividend

There's A Lot To Like About Shaanxi Panlong Pharmaceutical Group Limited By Share's (SZSE:002864) Upcoming CN¥0.22 Dividend

陝西盤龍藥業集團股份有限公司(深圳證券交易所:002864)即將派發的0.22元人民幣股息有很多值得喜歡的地方
Simply Wall St ·  05/30 20:20

It looks like Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd (SZSE:002864) is about to go ex-dividend in the next 2 days. Typically, the ex-dividend date is one business day before the record date which is the date on which a company determines the shareholders eligible to receive a dividend. The ex-dividend date is an important date to be aware of as any purchase of the stock made on or after this date might mean a late settlement that doesn't show on the record date. In other words, investors can purchase Shaanxi Panlong Pharmaceutical Group Limited By Share's shares before the 3rd of June in order to be eligible for the dividend, which will be paid on the 3rd of June.

看起來盤龍藥業股份有限公司(深圳證券交易所:002864)即將在未來2天進入除息日。一般來說,除息日是緊接着公告日的前一種工作日,公司可以以此時間確定那些獲得股息的股東。除息日非常重要,因爲在除息日之後購買該股,可能意味着結算時間過晚,不會在公告日上顯示。換句話說,投資者可以在6月3日之前購買盤龍藥業股份有限公司的股票,以便有資格獲得分紅,分紅將於6月3日支付。

The company's next dividend payment will be CN¥0.22 per share, and in the last 12 months, the company paid a total of CN¥0.22 per share. Based on the last year's worth of payments, Shaanxi Panlong Pharmaceutical Group Limited By Share has a trailing yield of 0.8% on the current stock price of CN¥28.98. If you buy this business for its dividend, you should have an idea of whether Shaanxi Panlong Pharmaceutical Group Limited By Share's dividend is reliable and sustainable. As a result, readers should always check whether Shaanxi Panlong Pharmaceutical Group Limited By Share has been able to grow its dividends, or if the dividend might be cut.

公司下一個分紅爲人民幣0.22元/股,在過去12個月內,公司每股派發了總額爲人民幣0.22元/股的分紅。根據去年的支付情況,盤龍藥業的股息收益率達到了當前每股人民幣28.98元的股價的0.8%。如果您因分紅而購買此股票,應了解盤龍藥業的股息是否可靠和可持續。因此,讀者應始終檢查盤龍藥業是否能夠增加其股息,或者股息可能會被削減。

Dividends are typically paid out of company income, so if a company pays out more than it earned, its dividend is usually at a higher risk of being cut. Shaanxi Panlong Pharmaceutical Group Limited By Share paid out just 18% of its profit last year, which we think is conservatively low and leaves plenty of margin for unexpected circumstances. Yet cash flows are even more important than profits for assessing a dividend, so we need to see if the company generated enough cash to pay its distribution. The good news is it paid out just 23% of its free cash flow in the last year.

分紅通常是從公司收入中支付的,因此,如果公司支付的股息高於其收入,其股息通常面臨更高的風險。盤龍藥業去年僅支付了其利潤的18%,我們認爲這相當保守,留有足夠的按金應對意外情況。但是,對於評估股息來說,即使比利潤更重要的是現金流,因此我們需要看看公司是否有足夠的現金來支付分配。好消息是,它在過去一年中只支付了其自由現金流的23%。

It's encouraging to see that the dividend is covered by both profit and cash flow. This generally suggests the dividend is sustainable, as long as earnings don't drop precipitously.

看到股息既有盈利也有現金流的覆蓋是令人鼓舞的。這通常表明股息是可持續的,只要收益沒有急劇下降。

Click here to see the company's payout ratio, plus analyst estimates of its future dividends.

點擊此處查看公司的支付比率以及未來分紅的分析師預期。

historic-dividend
SZSE:002864 Historic Dividend May 31st 2024
SZSE:002864歷史分紅情況截至2024年5月31日

Have Earnings And Dividends Been Growing?

收益和股息一直在增長嗎?

Companies with consistently growing earnings per share generally make the best dividend stocks, as they usually find it easier to grow dividends per share. If business enters a downturn and the dividend is cut, the company could see its value fall precipitously. This is why it's a relief to see Shaanxi Panlong Pharmaceutical Group Limited By Share earnings per share are up 8.8% per annum over the last five years. Earnings per share have been growing at a decent rate, and the company is retaining more than three-quarters of its earnings in the business. If profits are reinvested effectively, this could be a bullish combination for future earnings and dividends.

通常情況下,每股收益持續增長的公司通常成爲最好的股息股票,因爲它們通常更容易增加每股股息。如果企業進入下滑期並削減股息,則公司可能會看到其價值急劇下跌。這就是爲什麼值得欣慰的是,盤龍藥業過去五年的每股收益每年增長了8.8%。每股收益一直在以相當的速度增長,公司將超過四分之三的收益保留在業務中。如果利潤得到有效再投資,這可能是未來收益和股息的看好組合。

Shaanxi Panlong Pharmaceutical Group Limited By Share also issued more than 5% of its market cap in new stock during the past year, which we feel is likely to hurt its dividend prospects in the long run. It's hard to grow dividends per share when a company keeps creating new shares.

盤龍藥業在過去一年中發行的新股份超過了其市值的5%,我們認爲這可能會對其長期股息前景產生負面影響。當一家公司不斷髮行新股份時,很難增長每股股息。

The main way most investors will assess a company's dividend prospects is by checking the historical rate of dividend growth. Since the start of our data, six years ago, Shaanxi Panlong Pharmaceutical Group Limited By Share has lifted its dividend by approximately 14% a year on average. It's encouraging to see the company lifting dividends while earnings are growing, suggesting at least some corporate interest in rewarding shareholders.

大多數投資者評估公司分紅前景的主要方法是查看歷史分紅增長率。自六年前我們開始記錄數據以來,盤龍藥業股份有限公司的年均分紅增長率約爲14%。我們很高興看到公司在盈利增長的同時提高了分紅,這表明至少有一些企業有興趣獎勵股東。

To Sum It Up

總結一下

Should investors buy Shaanxi Panlong Pharmaceutical Group Limited By Share for the upcoming dividend? Earnings per share growth has been growing somewhat, and Shaanxi Panlong Pharmaceutical Group Limited By Share is paying out less than half its earnings and cash flow as dividends. This is interesting for a few reasons, as it suggests management may be reinvesting heavily in the business, but it also provides room to increase the dividend in time. We would prefer to see earnings growing faster, but the best dividend stocks over the long term typically combine significant earnings per share growth with a low payout ratio, and Shaanxi Panlong Pharmaceutical Group Limited By Share is halfway there. Shaanxi Panlong Pharmaceutical Group Limited By Share looks solid on this analysis overall, and we'd definitely consider investigating it more closely.

投資者是否應該買入盤龍藥業股份有限公司即將到來的分紅?每股收益增長有所增長,盤龍藥業股份有限公司支付的股息和現金流分別不足其收益的一半。這有幾個有趣之處,表明管理層可能正在大量再投資於業務中,但它也爲隨着時間的推移提高分紅提供了空間。我們希望看到盈利增長更快,但長期來看最好的股息股票通常將顯着的每股收益增長與低的支付比率相結合,而盤龍藥業股份有限公司已經完成了其中的一半。總體而言,盤龍藥業股份有限公司在這方面表現不錯,我們肯定會考慮進一步調查它。

In light of that, while Shaanxi Panlong Pharmaceutical Group Limited By Share has an appealing dividend, it's worth knowing the risks involved with this stock. For example - Shaanxi Panlong Pharmaceutical Group Limited By Share has 2 warning signs we think you should be aware of.

基於此,雖然盤龍藥業股份有限公司具有吸引力的股息,但了解與該股票有關的風險是值得的。例如,盤龍藥業股份有限公司有2個我們認爲您應該知道的警告信號。

If you're in the market for strong dividend payers, we recommend checking our selection of top dividend stocks.

如果你在尋找強勁的股息支付者,我們建議查看我們的頂級股息股票選擇。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或電郵 editorial-team (at) simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論